Pseudorabies virus deletion mutants involving the EPO and LLT genes
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsAndrew K. Cheung, Ronald D. Wesley
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsAndrew K. Cheung, Ronald D. Wesley
Estimating the term…
An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.
A pseudorabies virus having a genomic modification selected from the group consisting of a deletion, and insertion or both in:
A method of immunizing an animal against psuedorabies comprising administering to said animal a vaccine comprising a pseudorabies virus having a genomic modification selected from the group consisting of a deletion, and insertion or both in:
A method for producing a pseudorabies virus deletion mutant comprising the steps:
Dependencies are inferred from the claim text.